Phase III Test of Velcade, Formerly MLN341, in Multiple Myeloma
CAMBRIDGE, Massachusetts-Millennium Pharmaceuticals, Inc. has begun a pivotal phase III clinical trial of Velcade (bortezomib) (formerly known as MLN341, LDP-341, and PS-341) in patients with multiple myeloma. Velcade is designed to block proteasomes, enzyme complexes in the cell responsible for breaking down a variety of proteins, including many that regulate cell division, the company said in a press release.
CAMBRIDGE, MassachusettsMillennium Pharmaceuticals, Inc. has begun a pivotal phase III clinical trial of Velcade (bortezomib) (formerly known as MLN341, LDP-341, and PS-341) in patients with multiple myeloma. Velcade is designed to block proteasomes, enzyme complexes in the cell responsible for breaking down a variety of proteins, including many that regulate cell division, the company said in a press release.
The phase III trial is being planned for more than 60 sites in the United States, Canada, and Europe in approximately 600 patients with multiple myeloma whose disease has progressed despite one to three previous therapies. Patients will be randomly assigned to receive Velcade for Injection or high-dose dexamethasone.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
